Patents by Inventor Richard D. Garman

Richard D. Garman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8540999
    Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: September 24, 2013
    Assignee: Merck Patent GmbH
    Inventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-Chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
  • Patent number: 7482008
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: January 27, 2009
    Assignee: Merck Patent GmbH
    Inventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern, Julian F. Bond, Andrew W. Brauer, Malcolm Morville, Thomas J. Briner, Ze'ev Shaked
  • Patent number: 7288256
    Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: October 30, 2007
    Assignee: Merck Patent GmbH
    Inventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze'ev Shaked
  • Patent number: 7211408
    Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: May 1, 2007
    Assignee: Merck Patent GmbH
    Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
  • Patent number: 6982326
    Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: January 3, 2006
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
  • Publication number: 20040057959
    Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.
    Type: Application
    Filed: June 16, 2003
    Publication date: March 25, 2004
    Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
  • Publication number: 20030035815
    Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.
    Type: Application
    Filed: June 5, 1995
    Publication date: February 20, 2003
    Inventors: BRUCE L. ROGERS, JAY P. MORGENSTERN, JULIAN F. BOND, RICHARD D. GARMAN, JULIA L. GREENSTEIN, MEI-CHANG KUO, MALCOLM MORVILLE
  • Patent number: 6268491
    Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 31, 2001
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze′ev Shaked
  • Patent number: 6120769
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: September 19, 2000
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Julian F. Bond
  • Patent number: 6090386
    Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 18, 2000
    Inventors: Irwin J. Griffith, Joanne Pollock, Julian F. Bond, Richard D. Garman, Mei-chang Kuo, Stephen P. Powers, Mark A. Exley, Xian Chen, Ze'ev Shaked
  • Patent number: 6048962
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: April 11, 2000
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern, Andrew W. Brauer
  • Patent number: 6019972
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: September 2, 1994
    Date of Patent: February 1, 2000
    Assignee: ImmuLogic Pharmaceutical Corporation
    Inventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Malcolm Morville, Thomas J. Briner
  • Patent number: 5968526
    Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 19, 1999
    Assignee: Immulogic Pharamaceutical Corporation
    Inventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze'ev Shaked
  • Patent number: 5820862
    Abstract: The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides. Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 13, 1998
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Henry M. Franzen, Xian Chen, Sean Evans, Ze'ev Shaked
  • Patent number: 5547669
    Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.
    Type: Grant
    Filed: December 13, 1991
    Date of Patent: August 20, 1996
    Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Malcolm Morville